Cancer drug dasatinib takes aim at HIV's secret hiding spots
NCT ID NCT07342491
First seen Jan 18, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This early-stage study tests whether dasatinib, a drug used for cancer, can lower the amount of hidden HIV in the body (the HIV reservoir). Fourteen adults with well-controlled HIV on standard therapy will take either dasatinib or a placebo daily for 12 weeks. The goal is to see if the drug is safe and can reduce the hidden virus, but lifelong HIV medication will still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
1401, University of Washington Positive Research CRS
Seattle, Washington, 98104, United States
-
2501, Case CRS
Cleveland, Ohio, 44106, United States
-
Northwestern University CRS (Site # 2701)
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.